• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Maze Therapeutics (MAZE) Slides Despite A Stronger 1 Year Return, Is It Fully Valued?

    Simply Wall St·09/05/2026 12:26:30
    Listen to the news

    Maze Therapeutics (MAZE) has drawn fresh attention after recent trading left the stock down about 6% over the past month, even though its return over the past 3 months is positive.

    Over the past year, Maze Therapeutics has combined a share price that is down 34.1% year to date with a 1-year total shareholder return of 65.05%. This suggests recent weakness, including a 5.75% 30-day share price decline, comes after a strong longer term rebound in investor sentiment.

    Scan beyond Maze Therapeutics and compare this recent swing in sentiment with other hand picked biotech ideas in our 19 high quality undiscovered gems.

    Maze Therapeutics has swung from a sharp year to date decline to a strong 1 year total return, which leaves a simple question hanging for new money: Does the current price still offer a favourable risk reward before looking at valuation?

    Preferred Price to Book Multiple of 3.2x: Is it justified?

    Maze Therapeutics currently trades on a P/B ratio of 3.2x, compared with a US Pharmaceuticals industry average of 2.5x and a peer average of 3.6x.

    The P/B ratio compares the company’s market value with the book value of its net assets. For a clinical stage biopharmaceutical business like Maze Therapeutics, this measure often reflects how investors weigh pipeline potential and partnerships against current losses and the balance sheet.

    Maze Therapeutics is unprofitable today and reports a loss of $133.59m on revenue of $20.0m, yet the stock carries a P/B ratio that is higher than the broader industry but lower than its peer group. That suggests investors are assigning a premium to its asset base compared with the wider sector, while still valuing it at a discount to closer peers that trade on richer book value multiples.

    Compared with the US Pharmaceuticals industry, Maze Therapeutics looks expensive on a P/B basis, given its 3.2x ratio versus the 2.5x sector average. However, relative to a peer average P/B of 3.6x, the stock is priced at a lower multiple, which points to a more moderate valuation within its immediate comparison set.

    To see how this compares with where the P/B ratio could settle over time, review the fair ratio view in our Explore the SWS fair ratio for Maze Therapeutics.

    Result: Price to book ratio of 3.2x (ABOUT RIGHT)

    However, Maze Therapeutics still faces clear risks, including clinical trial setbacks for its lead programs and the ongoing impact of reporting a loss of $133.59m on $20.0m revenue.

    Find out about the key risks to this Maze Therapeutics narrative.

    Next Steps

    If the mix of recent weakness and past strength in Maze Therapeutics leaves you unsure, act while the data is fresh and shape your own view using the 1 key reward and 3 important warning signs.

    Looking for more investment ideas beyond Maze Therapeutics?

    If Maze Therapeutics has sharpened your focus, do not stop here. Use fresh data and clear filters to spot other stocks that better match your plan.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.